Shanghai Labway Clinical Laboratory Co., Ltd. provides third-party medical testing and pathological diagnosis services to medical institutions throughout China, alongside sales of in vitro diagnostic products including instruments, reagents, accessories, and consumables. The company offers comprehensive diagnostic solutions such as blood tests, biochemistry, immunology, microbiological examinations, molecular and cell genetic testing, flow cytometry, drug concentration monitoring, and allergen detection; it also delivers professional technical support to empower hospital laboratories, pathology departments, and central labs in reducing costs, mitigating risks, and enhancing service quality. Founded in 1993 and headquartered in Shanghai at Building 1, Lane 268, Linxin Road, Changning District, the company operates primarily in the diagnostics and research segment of China's healthcare sector, serving hospitals, clinics, and community health centers nationwide with approximately 1,365 employees.
In recent developments, Shanghai Labway's basic data platform for AI pathology diagnosis passed acceptance in 2024, advancing its technological capabilities in automated diagnostics. The company reported a projected net loss of CNY 107 million to 157 million for fiscal year 2024, amid challenges including share reductions by major shareholder Heilan Group, which sold shares equivalent to 4.98% of total share capital by December 2024. Leadership changes included the election of Zeng Weixiong as director and chairman in late 2024, alongside board approvals for final cash dividends on A shares payable in June 2025.